Skip to content
No picture yet

Pradaxa 110 mg – DIN 02312441

Pradaxa is Dabigatran Etexilate Mesylate 110 mg (capsule), sold in Canada. It is used for blood clots in the veins and blood clots in the lungs. It is supplied by Boehringer Ingelheim (Canada) Ltd Ltee. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Dabigatran Etexilate Mesylate 110 mg

Brand
Pradaxa
Strength
110 mg
Used for
Blood clots in the veins and blood clots in the lungs
Form
Capsule
Manufacturer
Boehringer Ingelheim (Canada) Ltd Ltee
Sold in
Canada
DIN
02312441

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Dabigatran Etexilate pills and guides

What is Dabigatran Etexilate used for?

Dabigatran Etexilate is used for blood clots in the veins and blood clots in the lungs.

Official uses from the US prescribing label

Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients

Dabigatran Etexilate Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.

Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients

Dabigatran Etexilate Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days.

Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients

Dabigatran Etexilate Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated.

Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery

Dabigatran Etexilate Capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery.

Treatment of Venous Thromboembolic Events in Pediatric Patients

Dabigatran Etexilate Capsules is indicated for the treatment of venous thromboembolic events (VET) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days.

Reduction in the Risk of Recurrence of Venous Thromboembolic Events in Pediatric Patients

Dabigatran Etexilate Capsules is indicated to reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated.

From the FDA-approved label on DailyMed (published Aug 05, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02312441.
  • It names Pradaxa, Dabigatran Etexilate Mesylate 110 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Pradaxa known as pradax by Boehringer Ingelheim (Canada) Ltd Ltee.

In Canada: prescription only.

Ingredients

Active: Dabigatran Etexilate (Dabigatran Etexilate Mesilate)

Other Dabigatran Etexilate pills